GSK (NYSE:GSK) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS

GSK (NYSE:GSK) announced its earnings results on Wednesday. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15, Zacks reports. GSK had a net margin of 7.97% and a return on equity of 50.62%. GSK updated its FY 2025 guidance to 2.090-2.130 EPS.

GSK Stock Down 1.8 %

Shares of NYSE GSK traded down $0.69 during trading on Thursday, hitting $37.01. The stock had a trading volume of 2,390,836 shares, compared to its average volume of 4,433,834. GSK has a 12 month low of $31.72 and a 12 month high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The company has a market capitalization of $76.71 billion, a PE ratio of 24.02, a PEG ratio of 1.38 and a beta of 0.64. The firm has a fifty day moving average of $34.17 and a two-hundred day moving average of $37.60.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GSK. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.